President Donald Trump purchased stock in several companies after his administration took actions that boosted their business, raising new questions about potential conflicts of interest and whether he's profiting from his official decisions, according to financial disclosures reviewed by Notus.
The investments include shares in Palantir Technologies, purchased months after his administration awarded the data analytics firm a major defense contract, as well as holdings in Axon Enterprise, which received federal law enforcement contracts, and Nvidia, which benefited from the administration's artificial intelligence initiatives.
While presidents are not subject to the same conflict-of-interest rules that apply to Cabinet officials and other federal employees, ethics experts say the pattern of investments creates at minimum an appearance problem. "The timeline is what matters here," explained Virginia Canter, chief ethics counsel at Citizens for Responsibility and Ethics in Washington. "If he's buying stock in companies after his administration helps them, that raises serious questions."
The Palantir investment is particularly striking. According to financial disclosure forms filed this week, Trump purchased between $100,000 and $250,000 in Palantir stock in December 2025—three months after the Pentagon awarded the company a $480 million contract for battlefield intelligence systems. The stock price has risen 34% since the contract announcement.
Similarly, the president bought Axon stock in January 2026, weeks after his administration announced a $150 million initiative to equip federal immigration enforcement officers with body cameras and tasers—equipment primarily manufactured by Axon. The company's stock jumped 12% on the news.
White House press secretary Karoline Leavitt defended the investments, saying the president "has every right to invest in American companies" and that he "does not make individual procurement decisions." She noted that similar contracts were awarded to these companies during previous administrations.
But ethics watchdogs point out that Cabinet officials would face criminal prosecution for such investments. "There's a federal law that prohibits executive branch employees from participating in matters that affect their financial interests," said Walter Shaub, former director of the Office of Government Ethics. "The only reason the president can do this is that Congress exempted him from that law—not because it's ethical, but because impeachment was supposed to be the remedy."
The investments stand in sharp contrast to the approach of recent presidents. Barack Obama held his investments in diversified mutual funds and Treasury bonds to avoid even the appearance of conflicts. George W. Bush similarly placed his assets in broad-based index funds. Both presidents argued that Americans needed to trust that policy decisions were made in the national interest, not personal profit.
Trump has taken a different approach, maintaining his real estate empire while in office and now actively trading individual stocks. His financial disclosure forms show dozens of stock purchases and sales during his second term, including investments in defense contractors, pharmaceutical companies, and technology firms that regularly interact with federal agencies.
Congressional Democrats immediately seized on the revelations. "This is exactly what the Founders worried about," said Senator Elizabeth Warren of Massachusetts. "A president using the powers of his office to enrich himself. It's corruption in plain sight."
Republican lawmakers have been largely silent on the issue, though some privately expressed discomfort. One Republican senator, speaking on condition of anonymity, told reporters: "It doesn't look great, but I'm not sure what we can do about it legally. The president isn't breaking any laws."
The investments may face scrutiny from multiple oversight bodies. The House Oversight Committee's ranking Democrat has requested documents showing when the president was briefed on contract awards versus when he made stock purchases. Several ethics organizations are exploring whether the pattern could constitute a violation of the Constitution's domestic emoluments clause, which prohibits the president from receiving compensation beyond his salary.
From Wall Street to Main Street, the revelations have sparked debate about whether America's ethics laws are adequate for the modern era. As Americans like to say, "all politics is local"—even in the nation's capital. But this case raises a fundamental question about national governance: should a president be allowed to profit from the very government decisions he controls?
